Showing results (121-130 of 189) with videos related to

Sort By:
Pageof 19
Hepatology (Baltimore, Md.)|April 3, 2021
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 TrialSamer Gawrieh, Mazen Noureddin, Nicole Loo, et al.
Diabetes Care|July 24, 2019
Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled TrialFernando Bril, Diane M Biernacki, Srilaxmi Kalavalapalli, et al.
Journal of the Endocrine Society|January 1, 2026
Improving MASLD Risk Stratification in Young Adults with Cardiometabolic Risk Factors and Insulin Resistance AssessmentAnu Sharma, Eddison Godinez Leiva, Srilaxmi Kalavalapalli, et al.
Journal of Hepatology|September 26, 2024
Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASHNaim Alkhouri, Cayden Beyer, Elizabeth Shumbayawonda, et al.
Annals of Internal Medicine|June 21, 2016
Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized TrialKenneth Cusi, Beverly Orsak, Fernando Bril, et al.
The Lancet. Gastroenterology & Hepatology|September 24, 2021
Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a studyKenneth Cusi, Naim Alkhouri, Stephen A Harrison, et al.
Diabetes Care|October 13, 2019
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 DiabetesFernando Bril, Michael J McPhaul, Michael P Caulfield, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|October 13, 2018
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitusFernando Bril, Michael J McPhaul, Michael P Caulfield, et al.
Journal of Hepatology|February 22, 2023
Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)Stephen A Harrison, Carole Thang, Sébastien Bolze, et al.
Journal of Hepatology|August 27, 2013
Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver diseaseKenneth Cusi, Zhi Chang, Steve Harrison, et al.
Pageof 19